Compare Organon & Co. Common Stock (OGN) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs NEOS S&P 500 High Income ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while NEOS S&P 500 High Income ETF trades at $53.55 (market cap $12.59B). The key difference: NEOS S&P 500 High Income ETF is far larger — about 3.5× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while NEOS S&P 500 High Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and NEOS S&P 500 High Income ETF for 59 Days on average.
| OGN | SPYI | |
|---|---|---|
Market Cap | $3.62B | $12.59B |
Volume | 2,892,999 | 1,834,804 |
Sector | Health | Income / Options Overlay |
52-Week High | $13.81 | $54.42 |
52-Week Low | $5.70 | $47.98 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SPYI trades at $54.11 with minimal daily movement (+0.02%). Technical indicators show a bullish trend with strong moving average support, though RSI suggests potential overbought conditions. Recent news highlights SPYI's role in income-focused portfolios while raising concerns about principal erosion from covered call strategies. The ETF's dividend payments remain consistent with recent distributions around $0.53-0.54 per share.
The outlook for SPYI balances high income generation against capital preservation risks. While the covered call strategy provides attractive yields, investors face potential principal erosion during market rallies. Recent analyst coverage suggests a cautious approach given the trade-offs between income stability and growth limitations inherent in the fund's strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
